Bahrain's National Health Regulatory Authority said on Sunday it had approved the registration of a coronavirus vaccine developed by China National Pharmaceutical Group (Sinopharm). The statement did not specify which vaccine among the two being developed by Sinopharm, but cited data from Phase III clinical trials that showed an 86% efficacy rate and said Bahrain had participated in those trials. The data cited was the same as what was announced earlier this month by the United Arab Emirates from interim analysis of late-stage clinical trials for an inactivated vaccine developed by Beiji
https://ift.tt/3gLpM8m
ليست هناك تعليقات:
إرسال تعليق